On April 30, 2026, the U.S. Food and Drug Administration announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from ...

Compounded semaglutide, tirzepatide and liraglutide could be harder to come by starting this summer, if the U.S. Food and ...

The US FDA has proposed an end to most types of compounding of semaglutide, tirzepatide, and liraglutide. The agency said in a statement it has determined there is no longer a clinical need for ...

The proposal could affect telehealth services that rely on outside facilities to produce the knockoff drugs in bulk.

On April 16, 2026, the U.S. Food & Drug Administration (FDA) announced it will convene the Pharmacy Compounding Advisory Committee (PCAC) on July ...

The FDA has moved to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular weight loss drugs -- ...

If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines ​unless they appear ...

The state Senate passed a bill Friday regulating copycat versions of popular weight loss drugs like Ozempic and Wegovy.

Discover how compounding pharmacies are transforming healthcare by creating tailor-made medications for patients with unique needs, offering critical alternatives when standard drugs fall short, and ...

Agency proposal would exclude semaglutide, tirzepatide, and liraglutide from 503B bulks li ...

Eli Lilly alleged that Empower lured customers away from their brand-name GLP-1 products and toward the pharmacy's ...

FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of ...